MD Anderson and KKR-Backed Replay Form New Product Company Syena To Pioneer First-In-Class TCR NK Cell Therapy
February 15, 2023
February 15, 2023
HOUSTON, Texas, Feb. 15 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release on Feb. 14, 2023:
* * *
Cord blood-derived T cell receptor natural killer (TCR NK) platform offers potential for scalable off-the-shelf cell therapy
* * *
The University of Texas MD Anderson Cancer Center and Replay today announced the launch of Syena, a new oncology-focused product company pioneering T cell receptor (TCR) n . . .
* * *
Cord blood-derived T cell receptor natural killer (TCR NK) platform offers potential for scalable off-the-shelf cell therapy
* * *
The University of Texas MD Anderson Cancer Center and Replay today announced the launch of Syena, a new oncology-focused product company pioneering T cell receptor (TCR) n . . .